PATENT CLAIM ANALYSIS

Application Number: 16376216
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-08
Patent Classification: ["424", "085700"]

Abstract:
Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g., EGFRvIII-expressing cells that also express interferon receptors) and that induce anti-proliferative effects, and related compositions and methods for the treatment of cancer

Claim (Index 9):
The fusion protein of  claim 1 , wherein the net charge of the linker is negative.

Metadata:
- Claim Count in Document: 24.0
- Percentile: 100.0
- Lexical Diversity: 1.36585
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15307646', '12985122', '15359456', '12541062', '12610204']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7326552546966728
- 35 USC 102 Novelty (BERT): 0.66783925375596
- Combined Prediction Score: 0.7261736546026015
- Mean Citation Score: 379.304904
- Max Citation Score: 669.4451
- Similarity Product: 583.8600978639007

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test